The baroreceptor as a therapeutic target for heart failure.

Item

http://www.wikidata.org/entity/Q38190492

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

The baroreceptor as a therapeutic target for heart failure.

@en

type

Item

label

The baroreceptor as a therapeutic target for heart failure.

@en

prefLabel

The baroreceptor as a therapeutic target for heart failure.

@en

P1476

The baroreceptor as a therapeutic target for heart failure.

@en

P2093

Dimitrios Georgakopoulos

http://www.w3.org/2001/XMLSchema#string

Edoardo Gronda

http://www.w3.org/2001/XMLSchema#string

Emilio Vanoli

http://www.w3.org/2001/XMLSchema#string

Eric G Lovett

http://www.w3.org/2001/XMLSchema#string

Guido Grassi

http://www.w3.org/2001/XMLSchema#string

Michela Tarascio

http://www.w3.org/2001/XMLSchema#string

P2860

Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

The ion channel ASIC2 is required for baroreceptor and autonomic control of the circulation.

Sustained suppression of sympathetic activity and arterial pressure during chronic activation of the carotid baroreflex

Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.

Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial.

Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial.

Carotid sinus baroreceptor sensitivity in experimental heart failure.

Cardiac-resynchronization therapy in heart failure with a narrow QRS complex.

P2888

s12265-014-9546-8

P304

301-309

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12265-014-9546-8

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260376046

http://www.w3.org/2001/XMLSchema#string

P6179

1023668216

http://www.w3.org/2001/XMLSchema#string

P698

24563340

http://www.w3.org/2001/XMLSchema#string